Drug Trial Radar · NCT05374564
Parametric Cardiac 18F-flutemetamol PET Imaging in ATTR Cardiomyopathy
Last checked: Nov 20, 2026Latest source record: Aug 3, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
12
Actual
Start
Aug 16, 2022
Primary completion
Nov 14, 2024
Study completion Nov 14, 2024
Sponsor
- Lead sponsor
- Yale UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Pfizer
- First posted
- May 16, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Diagnostic
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
18F-Flutemetamol (Vizamyl) is a radioactive diagnostic agent indicated and FDA-approved for Positron Emission Tomography (PET) imaging of the brain to estimate β-amyloid neuritic plaque density in adult patients with cognitive impairment who are being evaluated for Alzheimer's disease (AD) or other causes of cognitive decline. This study is designed to evaluate a novel use for 18F-Flutemetamol in cardiac amyloidosis.
Conditions
- Cardiomyopathies, Primary
Interventions
(18F)FlutemetamolDrug
18F-Flutemetamol binds to β-amyloid plaques and the F-18 isotope produces a positron signal that is detected by a PET scanner. Multiple recent studies have shown that thioflavin-analogue tracers such as 18F-flutemetamol may be able to fulfill the unmet need of elucidating the presence of amyloid deposition in the heart. Because it binds to the beta-pleated motif of the amyloid fibril due to their similarity to the thioflavin structure, 18F-Flutemetamol could potentially be used to image cardiac amyloidosis (CA)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Determine if ATTR cardiomyopathy disease severity is associated with increased 18F-flutemetamolTime frame: 6 months
- Determine if ATTR cardiomyopathy disease severity is associated with increased 18F-flutemetamolTime frame: 6 months
- Determine if ATTR cardiomyopathy disease severity is associated with increased 18F-flutemetamolTime frame: 6 months
- Determine if ATTR cardiomyopathy disease severity is associated with increased 18F-flutemetamolTime frame: 6 months
- Determine if ATTR cardiomyopathy disease severity is associated with increased 18F-flutemetamolTime frame: 6 months
- Determine if treatment with tafamidis reduces 18F-flutemetamol cardiac PET imaging markersTime frame: 6 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Yale University
New Haven, Connecticut
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.